OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, Mike Dymond, Anitra Fielding, A. Allen, PierFranco Conte
Topics & Concepts
OlaparibMedicineHazard ratioInternal medicineOncologyMetastatic breast cancerBRCA mutationPopulationConfidence intervalCancerBreast cancerGynecologyBiologyPoly ADP ribose polymeraseEnvironmental healthGenePolymeraseBiochemistryPARP inhibition in cancer therapyAdvanced Breast Cancer TherapiesBRCA gene mutations in cancer